We performed a genomewide association study (GWAS) of primary erythrocyte thiopurine S-methyltransferase (TPMT) activity in children with leukemia (n 5 1,026). Adjusting for age and ancestry, TPMT was the only gene that reached genomewide significance (top hit rs1142345 or 719A>G; P 5 8.6 3 10 -61
, WE Evans 1 , S Bhatia 3 and MV Relling 1 We performed a genomewide association study (GWAS) of primary erythrocyte thiopurine S-methyltransferase (TPMT) activity in children with leukemia (n 5 1,026). Adjusting for age and ancestry, TPMT was the only gene that reached genomewide significance (top hit rs1142345 or 719A>G; P 5 8. 6 3 10 -61 ). Additional genetic variants (in addition to the three single-nucleotide polymorphisms [SNPs] , rs1800462, rs1800460, and rs1142345, defining TPMT clinical genotype) did not significantly improve classification accuracy for TPMT phenotype. Clinical mercaptopurine tolerability in 839 patients was related to TPMT clinical genotype (P 5 2. 4 3 10 -11 ). Using 177 lymphoblastoid cell lines (LCLs), there were 251 SNPs ranked higher than the top TPMT SNP (rs1142345; P 5 6.8 3 10 -5 ), revealing a limitation of LCLs for pharmacogenomic discovery. In a GWAS, TPMT activity in patients behaves as a monogenic trait, further bolstering the utility of TPMT genetic testing in the clinic.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? þ Dose-limiting toxicity due to TPMT defects resulted in treatment interruptions. Genotypic and phenotypic assays of TPMT activity in patients are used to adjust doses of thiopurines, assuming TPMT genotyping has adequate sensitivity and specificity.
WHAT QUESTION DID THIS STUDY ADDRESS?
þ This pharmacogenomics study evaluated the contribution of genetic variation in TPMT and other genes to TPMT activity, and their effects on thiopurine tolerance in two ALL cohorts.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE þ TPMT activity behaves as a monogenic trait in both cohorts. Additional genetic variants (besides the three SNPs [rs1800462, rs1800460, and rs1142345] defining TPMT clinical genotype) did not substantially improve classification accuracy for TPMT phenotype. HOW THIS MIGHT CHANGE CLINICAL PHARMA-COLOGY OR TRANSLATIONAL SCIENCE þ This study confirms that current strategies for clinical TPMT genetic testing based on only three genomic variants adequately classify patients for their TPMT phenotype, thereby bolstering the use of TPMT genetic testing to assess TPMT status in the clinic.
Thiopurine S-methyltransferase (TPMT) genomic variation has been associated with toxicities from mercaptopurine, a critical component in the treatment of autoimmune diseases, acute lymphoblastic leukemia (ALL), and lymphomas.
1,2 Dosage individualization based on TPMT genotype or erythrocyte enzymatic activity (phenotype) is recommended for patients receiving thiopurines. 3 Without individualizing thiopurine doses based on TPMT, toxicity due to TPMT defects results in treatment interruptions, 2, 4 which have been associated with worse outcomes. [5] [6] [7] Although TPMT activity has been strongly related to TPMT genotype, it may be influenced by other genes. A genomewide study using HapMap CEU lymphoblastoid cell lines (LCLs) showed that a TPMT haplotype predicted TPMT activity, but there were also 96 genes ranked higher than TPMT. 8 Variation in erythrocyte TPMT activity within those who are wild-type for TPMT variants raises the question of whether there are other genetic modifiers of TPMT activity. [9] [10] [11] Moreover, racial and ethnic differences exist; patients of African ancestry have lower TPMT activity [12] [13] [14] and lower levels of methylated metabolites 15 than other populations, and Asian patients were relatively intolerant to thiopurines, 16 despite their low frequency of TPMT variant alleles. 17 However, a non-TPMT genetic basis for racial variation in TPMT activity is not known. Current strategies for clinical TPMT genetic testing include three variants: rs1800462 (238G>C), rs1800460 (460G>A), and rs1142345 (719A>G). Here, we studied two ethnically diverse cohorts of children with ALL using agnostic genomewide association study (GWAS) approaches to evaluate the contribution of genetic variation in TPMT and other genes to TPMT activity and effects on thiopurine tolerance, and to determine whether current TPMT genetic testing adequately classifies patients for their TPMT phenotype.
RESULTS
Among the 1,026 patients who had TPMT clinical genotype (Table 1) , TPMT activity displayed normal distributions within the 938 patients whose TPMT clinical genotype was wild-type and the 87 heterozygotes who carried a known no-function variant of *2, *3A, or *3C (Figure 1a) . Heterozygous patients showed lower TPMT activity (median 5 10.4 U/mL erythrocytes; range 5 6.3-17.0 U/mL) than wild-type patients (median 5 19.8 U/mL; range 7.1-33.1 U/mL; P 5 1. 2 3 10 -73 ). The one homozygous-deficient patient (who carried *3A and *3C) had negligible activity of 0.5 U/mL. The percentage of TPMT heterozygotes tended to be higher in black patients (13%) than in white patients (9%, v 2 P 5 0.19; Figure 1b) . Overall, black patients (n 5 138) also had lower TPMT activity than nonblack patients did (n 5 825; P 5 7.7 3 10 -8 ). In a multivariate model, TPMT clinical genotype was the strongest determinant of erythrocyte TPMT activity after adjusting for clinical characteristics and genetic ancestry (meta-analysis P 5 2.3 3 10 -67 ; Table 2 ). African ancestry (meta-P 5 1.4 3 10 -7 ) and older age (meta-P 5 6.6 3 10 -4 ) were also associated with lower TPMT activity in both St Jude (SJ) and Children's Oncology Group (COG) cohorts after adjusting for TPMT clinical genotype.
Seven coding variants (alleles TPMT*2, *3A, *3C, *8, *12, *24, and *40) were identified among 306 SJ and 578 COG patients who had Affymetrix 6.0 and exome array data (see Supplementary Table S1 online). Genotypes of the three no-function variants (*2, *3A, and *3C) based on exome array were 100% concordant with the clinical genotypes determined using polymerase chain reaction. Similar to previous reports, 18, 19 TPMT diplotypes varied substantially by race ( Table 3) . TPMT*3A was most prevalent in white (34/360; 9.5%) and Hispanic patients (17/242; 7.0%), but was completely absent in black patients (0/131). In contrast, TPMT*3C was the predominant variant allele in black patients (16/131, 12.2%), but was rare in white patients (1/360; 0.3%) and Hispanic patients (2/242; 0.8%). No Asian patients (n 5 55) carried any variant alleles. Patients heterozygous for the TPMT*24 allele (537G>T) had activity that was intermediate (n 5 10; median 5 14.2 U/mL; range 5 8.0-23.9 U/mL) between those of TPMT clinical heterozygotes (P 5 3.9 3 10 -8 ) and *1/*1 wild-types (P 5 0.002). TPMT*8 (644G>A), a variant that has been associated with African ancestry, 18 was found in five African American patients, one white patient, and two patients in the "other" race group. Patients who carried a *8 allele tended to have TPMT activity (median 5 14.7 U/mL; range 5 12.1-21.1 U/mL; Figure 2 ) that was lower than those with TPMT*1/*1 (median 5 18.6 U/mL; range 5 7.1-33.1 U/mL; P 5 0.15) but higher than those with heterozygote clinical genotype including *2, *3A, or *3C (P 5 3.9 3 10 -8 ). The TPMT*40 allele (677G>A) was found in one Hispanic patient with an intermediate activity of 12.8 U/mL. The GWAS for TPMT activity was performed in two cohorts of 306 SJ and 578 COG patients separately (Figure 3a and 3b) , and followed by a meta-analysis that combined the results from the two cohorts (Figure 3c ). After adjusting for age and ancestry, we observed a strong association between TPMT activity and polymorphisms in the TPMT region. There were 94 typed or imputed single-nucleotide polymorphisms (SNPs; coding and noncoding) with a meta-analysis P value that reached genomewide significance (P < 5 3 10 -8 ), all within 27kb of the TPMT gene (see Supplementary Table S2 online). Five of the 94 SNPs were interrogated on the arrays, including two missense variants, rs1142345 (719A>G; P 5 8. 6 3 10 -61 ) and rs1800460 (460G>A; P 5 2.0 3 10 ). The five SNPs were in the same linkage disequilibrium (LD) block (see Supplementary Figure S1 online) . Using a linear model, the three clinical no-function alleles of TPMT (*2, *3A, and *3C) explained 24.9% of variability of TPMT activity. When we add to the model the Genetic ancestries (European, African, Native American, and Asian) were determined in 306 SJ patients and 657 COG patients using STRUCTURE, 22 and either treated as a continuous variable or used to categorize patients as white (European ancestry >90%), black (African ancestry >70%), Hispanics (non-black patients with Native American ancestry >10%), Asian (Asian ancestry >90%), and "other" groups.
b
TPMT clinical genotype was determined using peripheral blood DNA at the beginning of remission induction, using polymerase chain reaction to detect the presence of three known no-function variants: rs1800462, rs1800460, and rs1142345 (contributing to *2, *3A, and *3C alleles) and categorized as HOM, HET, or WT.
coding variants for the alleles *8, *12, *24, and *40, 25.6% of the variability was explained (an increase of only 0.7%). The 92 SNPs that reached genomewide significance (the 94 SNPs in Supplementary Table S2 online, excluding the clinical SNPs of rs1142345 and rs1800460) accounted for another 0.9% in TPMT activity variability beyond that explained by the clinically tested alleles of *2, *3A, and *3C.
To estimate the possible contribution of additional rare variants (beyond those interrogated on arrays) to TPMT activity, we took two approaches. First, we sequenced the TPMT locus in a subset (n 5 296) of SJ patients. We detected 121 SNPs in TPMT and its adjacent region, and found 10 SNPs (all of them intronic and with common minor allele frequency (MAF)) were associated with TPMT activity (P < 0.05) after adjusting for clinical genotype (see Supplementary Table S3 online), with the highest ranked SNP rs115104049 (upstream of TPMT) having P 5 0.0003. The 10 variants explained 3.8% of variability of the TPMT activity in this subset of SJ patients, compared with 34% of variability explained by *2, *3A, and *3C in the SJ subset. Second, we performed a simulation based on TPMT variants that have been deposited in the Exome Aggregation Consortium dataset (see Supplementary Table S4 online) . 20 Among the 89 variants identified in >60,000 individuals, 41 were predicted to be damaging; after excluding the three common variants, the 38 variants are very rare (MAF <0.05%). Assuming these rare damaging TPMT variants have similar effect sizes as do The P values and coefficients are estimated using multivariate linear regression models. Regression coefficient indicates increase (positive) or decrease (negative) in TPMT activity (U/mL) with the presence of categorical variables (e.g., gender) or with certain levels of change in continuous variables (e.g., every 1 year increase in age). For example, patients with 100% African ancestry are estimated to be 2.72 U/mL lower than those who are 100% European ancestry. Meta-analysis is performed on the results from SJ and COG patients using Stouffer's Z-score combined P value method. COG, Children's Oncology Group; SJ, St Jude Children's Research Hospital; TPMT, thiopurine methyltransferase.
a Number of known no-function alleles (*2, *3A, or *3C), (i.e., homozygous deficiency 5 2, heterozygous 5 1).
ARTICLES
TPMT*2/*3A/*3C, we estimate that 1.2% (95% confidence interval 5 0.78-1.65%) of variation in TPMT activity could possibly be explained by additional rare TPMT variants, indicating a likely minimal contribution of other SNPs in the locus.
To identify whether there were non-TPMT genetic determinants, we conducted a second GWAS using TPMT clinical genotype as a covariate, and, after adjusting for age, ancestry, and TPMT clinical genotype, we observed a locus in the ADCY2 gene associated with TPMT activity in 306 SJ patients (see Supplementary Table S5 online and Supplementary Figure S2A online). The top hit (P 5 3.3 3 10 -8 ) consisted of four imputed SNPs, all of which are in complete LD (r 2 5 1). Among the genotyped SNPs, an intronic SNP, rs2892635, in ADCY2 ranked the highest (P 5 2.5 3 10 -7 ). This SNP was associated with higher TPMT activity across all race groups in SJ (see Supplementary Figure S3 online). However, none of the top-ranked variants, including rs2892635, were replicated in the COG cohort at the P < 0.05 level. Among the 578 COG patients, the top non-TPMT hit associated with TPMT activity was a missense SNP, rs142134087, in ARHGEF11 (P 5 2.0 3 10 -8 ; see Supplementary Table S6 online and Supplementary Figure S2b online). This SNP was rare in the COG cohort (MAF 5 0.2%) and absent in the SJ cohort; two individuals who were heterozygous for rs142134087 had high TPMT activity (with a mean of 31.9 U/mL). We also identified a SNP in a purine metabolism gene, FHIT (rs75341016; P 5 3.7 3 10 -7 ) associated with decreased TPMT activity. However, the topranked non-TPMT SNPs for the COG cohort did not reach P < 0.05 in the SJ cohort. In the meta-analysis of non-TPMT SNPs, no SNP reached genomewide significance (see Supplementary Table S7 online and Supplementary Figure S2c online); rs1345390 in FTO was the top-ranked genotyped SNP associated with increased TPMT activity in SJ (P 5 4.5 3 10 -3 ) and COG patients (P 5 7.9 3 10 -5 ), and in the meta-analysis (P 5 1.6 3 10 -6 ). We also assessed whether TPMT was the strongest genetic determinant of TPMT activity in HapMap LCLs. TPMT activity in the 88 YRI cell lines (median 5 16.7 U/mL; range 0.2-46.6 U/mL) was lower than that in the 89 CEPH cell lines (median 5 26.0 U/mL; range 5 9.1-98.0 U/mL; P 5 9.9 3 10 -14 ), consistent with the observation that African ancestry was associated with lower activity in patients ( Table 2 and Figure 1b) . Analyzing 4 million SNPs, no SNP reached genomewide significance. Unlike for primary erythrocyte data in patients, the top-ranked SNPs for cell lines did not include TPMT SNPs. The highest ranked SNP within TPMT was rs1142345 (719A>G), which only ranked 252 (P 5 6.8 3 10 -5 ) among all SNPs (see Supplementary Table S8 online). Among TPMT diplotypes were determined using the Exome Array data, and categorized as HOM, HET, or WT. Race was categorized using genetic ancestries: white (European ancestry >90%), black (African ancestry >70%), Hispanics (non-black patients with Native American ancestry >10%), Asian (Asian ancestry >90%), and other. Figure 2 Thiopurine methyltransferase (TPMT) activity by diplotypes in the combined cohort (n 5 884). TPMT activity was measured in 306 St Jude Children's Research Hospital (SJ) and 578 Children's Oncology Group (COG) patients whose TPMT diplotypes were determined using Illumina Human Exome Beadchip Array. TPMT heterozygous (HET) was defined as the presence of known no-function alleles *2, *3A, or *3C (shown in dashed box). The P values between diplotypes were determined using a general linear model that included protocol as covariate.
the 94 SNPs that were genomewide significant in patients (see Supplementary Table S2 online), 10 were also genotyped in LCLs, and 5 were associated with TPMT activity at the P < 0.05 level.
To partially address the striking difference in the ranking of TPMT SNPs for primary data in patients' erythrocytes compared to the cell line data, we performed 20 random permutations in the SJ and COG cohorts separately, using the same number of patients (n 5 177) and the same model used for the GWAS of the HapMap LCLs. Among 169,521 coding SNPs interrogated in the permutations, TPMT rs1142345 remained as the highest ranked with P values ranging from 3.8 3 10 -7 to 6.2 3 10 -13 (see Supplementary Figure S4 online). The top-ranked SNPs associated with TPMT activity in the permutation tests were similar to those from the patient GWAS in the two separate cohorts (data not shown).
We evaluated the classification performance of TPMT clinical genotype (based on three SNPs) to predict phenotype (see Supplementary Figures S5 and S6 online) . The threshold value for TPMT activity to divide patients with intermediate vs. normal TPMT activity can vary. Using a threshold of 14 U/mL, the sensitivity and specificity of clinical genotype in predicting "intermediate-activity phenotype" was 85% and 92% in the SJ cohort, and 98% and 84% in the COG cohort, respectively. Using an optimal threshold to distinguish TPMT phenotypes determined by the receiver operating characteristic curve (15 U/ mL for SJ and 13 U/mL for COG), the sensitivity and specificity were improved to 90% and 91% for SJ, and 94% and 91% for COG, respectively (see Supplementary Figure S5 online). The predictive capacity of clinical genotype based on the three SNPs, as evaluated by the area under the curve of the receiver operating characteristic curves, was >0.95 in both cohorts. Adding other TPMT variants, such as the *8 and *24 alleles, or the three genomewide significant SNPs (rs11964408, rs6908777, and rs16880220) did not improve the classification performance of clinical TPMT genotype to assess phenotype (see Supplementary  Figure S6 online).
Because TPMT activity relates to mercaptopurine toxicity, we studied the association between the top-ranked TPMT SNPs and mercaptopurine tolerance. The median dose intensities in TPMT heterozygotes who carried one *2, *3A, or *3C allele was 63%, 59%, and 72%, respectively, which were lower than in those with *1/*1 genotype (median 5 86%; P 5 2.4 3 10 -11 after adjusting for the protocol; Figure 4 ). The homozygous-deficient patient tolerated only 6% of protocol-defined mercaptopurine therapy. Using a threshold of 80% of protocol dose (see Supplementary  Figure S7 online) to distinguish high from low dose intensity, the negative predictive value of TPMT heterozygous genotype is 61% (i.e., 39% patients who had "wild-type" TPMT genetic testing still missed >20% of their thiopurine doses). There was no statistically significant difference between the dose intensity in *1/*1 patients and those who carried *8, *12, *24, or *40 variant alleles. After adjusting for protocol, TPMT clinical genotype, and clinical features, we did not observe a strong association between dose intensity and other genetic factors for TPMT activity, including rs1345390 (FTO; P 5 0.34), rs2892635 (ADCY2; P 5 0.09), and rs142134087 (ARHGEF11; P 5 0.79). As we reported, 21 the NUDT15 variant rs116855232 was associated with thiopurine dose intensity in the two cohorts (SJ P 5 0.030 and COG P 5 7.3 3 10 -11
), but it was not associated with TPMT activity (P 5 0.9). Addition of this variant did not affect the association between TPMT clinical genotype and dose intensity (P 5 1.7 3 10 -13
). Children's Oncology Group (COG) patients, and (c) meta-analysis based on the combined results from SJ and COG patients using Stouffer's Z-score method. The P values were determined using a general linear model after adjusting for genetic ancestry.
DISCUSSION
Thiopurines are commonly used for autoimmune diseases and for therapy of ALL. TPMT genotype is an indicator for the starting dose of thiopurines, 22 and has been advocated to prevent toxicities in those with TPMT defects without compromising treatment outcome. 4, 23 However, some studies suggested that TPMT genotype might not be a perfect predictor for the phenotype with a concordance of 53-100% in heterozygotes. 24 In addition, not all TPMT wild-type patients tolerated the full dose of mercaptopurine; the average dose intensity for wild-types ranged between 80 and 85%. 21, 25 Herein, we confirmed that TPMT activity is a monogenic pharmacogenomic trait in two independent ALL cohorts with diverse racial backgrounds using a genomewide agnostic approach. The GWAS for TPMT activity ( Figure 3 ) revealed a strong association in the TPMT region: all 94 genomewide significant SNPs were in or adjacent to TPMT (see Supplementary Table S2 online). This is most likely because they are in LD with no-function variants in TPMT (see Supplementary Figure S1 online). Heterozygosity at the three commonly tested no-function variants (*2, *3A, and *3C) was associated with lower TPMT activity and lower dose intensity than those with *1/*1 genotype (Figures 2 and 4) . Patients with *1/*8 (very common in African Americans) or *1/*24 genotypes had intermediate TPMT activity but tolerated normal dose intensity compared to those with *1/*1, partially supporting the current categorization of these patients as TPMT wild-types. TPMT*40 (677G>A at rs139392616) was described by Udaka et al. 26 by sequencing the TPMT gene in 288 individuals; however, its phenotype is not clear. Herein, we observed one Hispanic patient (MAF 5 0.2% in Hispanics) who carried TPMT*40, and this patient had intermediate TPMT activity of 12.8 U/mL. Of 11, 566 Latino subjects in the Exome Aggregation Consortium dataset, three individuals were heterozygous for this variant, yielding an MAF of 0.03%.
TPMT clinical genotype based on only three SNPs had high predictive capacity for TPMT phenotype (see Supplementary  Figure S5 online). Although TPMT*8, TPMT*24, and three intronic variants detectable by arrays were associated with intermediate or low TPMT activity in the entire cohort ( Figure 2 and Supplementary Table S1 online), we were unable to significantly improve the test performance by considering these additional variants (see Supplementary Figure S6 online). As expected, sequencing does detect additional variants not interrogated by arrays: in the relatively small subset of 296 SJ patients with sequencing data, these additional variants explained 3.8% variability in TPMT activity, compared to the 34% of variability accounted for by clinical genotyping (based on three SNPs). To extrapolate the possible contribution of rare variants to TPMT activity based on sequencing data from a much larger sample size (the 60,000 individuals in Exome Aggregation Consortium), we estimated that additional rare TPMT variants only explain an additional 1.2% of variation in TPMT activity beyond that explained by the three clinically genotyped variants. Unlike some other drug metabolism/disposition genes, no-function TPMT variants are relatively common and rare no-function alleles are less common, 27, 28 confirmed by lower population fixation index values. 29 Thus, genotyping of the three no-function SNPs (rs1800462, rs1800460, and rs1142345) is still the most reliable method to determine TPMT phenotype, and rare variants may be less of a problem for TPMT than for other actionable pharmacogenes.
We found no non-TPMT genes with a significant effect on TPMT activity in this GWAS. Given an alpha level of 1 3 10 -7 , we had 80% power to detect any SNPs with an MAF of at least 5% with an effect size of 40% of those of TPMT variants. There could be trans-SNPs with weaker effect sizes or lower MAFs that could influence TPMT activity, but a larger sample size would be needed to discover those SNPs.
After adjusting for TPMT genotype, TPMT activity was associated with variants in ADCY2 among SJ patients and with ARHGEF11 among COG patients (see Supplementary  Figure S2 online). However, the top variants that were identified in one cohort failed to replicate in the other cohort (see Supplementary Tables S5 and S6 online). The reasons for the conflicting results between the two cohorts may include: (1) the SJ protocol used a TPMT-guided dosing strategy whereas the COG protocol did not; (2) the top variant in the COG cohort (rs142134087 in ARHGEF11) was rare and absent in the SJ cohort; and (3) the variants have small effect sizes and require higher sample sizes to replicate. In any case, the effect of additional genetic factors on TPMT activity was not comparable to the effect of TPMT genotype.
Variants in FTO 30,31 were modestly associated with TPMT activity (see Supplementary Table S7 online). Interestingly, overexpression of FTO upregulated the expression of TPMT in mice. 32 However, in this study, the FTO variants only accounted for a minor change in TPMT activity: among the 896 patients wild-type for TPMT clinical genotype, those with two vs. one vs. zero C alleles at rs1345390 had a median activity of 19.5, 19.0, and 18.2 U/mL vs. (P 5 7.3 3 10 -6 after adjusting for clinical features). Overall dose intensity (i.e., prescribed dose/protocol dose) during maintenance therapy was estimated in 261 St Jude Children's Research Hospital (SJ) patients and 578 Children's Oncology Group (COG) patients whose thiopurine methyltransferase (TPMT) diplotypes were determined using Illumina Human Exome Beadchip Array. TPMT heterozygous (HET) was defined as the presence of the known no-function alleles *2, *3A, or *3C (shown in dashed box). The P values between diplotypes were determined using a general linear model that included protocol as covariate.
The HapMap project has been a useful resource in pharmacogenomic studies. Here, we showed that TPMT variant rs1142345 was associated with TPMT activity in 177 HapMap LCLs but only ranked 252 among all HapMap SNPs (see Supplementary Table S8 online), whereas the permutation tests in patients showed that rs1142345 was always top-ranked (see Supplementary Figure S4 online). It should be noted that rs1142345 is in complete LD with the TPMT haplotype (named HAP1) that we previously reported as the highest ranked TPMT SNP associated with TPMT activity in HapMap CEU LCLs. 8 The difference between the results from LCLs and from patients may be attributed to different conditions in cultured cell lines and in vivo, particularly because LCLs are transformed by Epstein-Barr virus infection, which may impact genetic regulation. 33 In the current study, we accounted for different LCL growth rates, 8, 9 and for the time gap between transformation of LCLs from CEU and from YRI samples 34 by adjusting for genetic ancestries. However, gene expression in LCLs may be affected by Epstein-Barr virus copy number. 35 Non-genetic factors may also have an impact on enzyme function in LCLs. 36 Moreover, TPMT activity may differ in lymphocytes vs. erythrocytes. 37 We have reported previously that the expression of PACSIN2 and its cis-SNP (rs2413739) were related to TPMT activity in 30 HapMap CEU trios. 9 In the current study, rs2413739 was not associated with TPMT activity in patients (P 5 0.14 and 0.54 in SJ and COG, respectively, after adjusting for TPMT clinical genotype). We compared our results with another study that used a pathway approach:
38 among the top-ranked SNPs from that study, only the two SNPs in TPMT were replicated in our study of HapMap LCLs and in SJ and COG patients (see Supplementary Table S9 online). Thus, LCLs may serve as a valuable resource for validating GWAS results, but their use for discovery may be challenging. 8 Race-specific differences in TPMT activity and mercaptopurine metabolism have been observed, [12] [13] [14] [15] [16] [17] and African ancestry has been related to lower TPMT activity [12] [13] [14] and lower levels of methylated metabolites. 15 Some studies reported a higher prevalence of TPMT variants in black patients 21 but other did not. 18, 39 In the current study, black patients had a lower TPMT activity compared to non-black patients (P 5 7.7 3 10 -8 ), and tended to have a higher frequency of no-function variants than white patients (P 5 0.19; Figure 1b ). The addition of TPMT genotype to the multivariate model did not affect the association of African ancestry with low activity ( Table 2 ), suggesting that other genetic factors may be involved; however, in a metaanalysis of African-ancestry patients only (SJ n 5 44 and COG n 5 87), all genomewide significant SNPs (n 5 21) locate within TPMT, similar to the observation in all patients. After adjusting for TPMT genotype, we were unable to find additional strong genetic associations (P < 10 -6 ) with TPMT activity (data not shown). Given that black patients tend to have a high risk of relapse [40] [41] [42] and that TPMT activity might be associated with relapse risk, 23, 43, 44 genetic and nongenetic factors should be considered in dose individualization in those patients.
There have been conflicting reports on the relationship between age and TPMT activity. [45] [46] [47] [48] [49] Here, we observed that older age was associated with lower TPMT activity after adjusting for TPMT genotype in both cohorts ( Table 2) . In summary, we used a genomewide agnostic approach to confirm that TPMT activity was a monogenic trait, and that current strategies for clinical TPMT genetic testing based on only three genomic variants adequately classify patients for their TPMT phenotype in a multiethnic cohort, thereby bolstering the use of TPMT genetic testing to assess TPMT status in the clinic.
METHODS

Patients and phenotypes
We studied 1,026 children with ALL, including 306 treated on St. Jude Children's Research Hospital Total Therapy XV (NCT00137111) 40 and 720 treated on the Children's Oncology Group (COG) clinical trial AALL03N1 (NCT00268528) 21 ( Table 1) . These patients were included in a previous study of mercaptopurine tolerability. 21 SJ Total XV was approved by the institutional review board at SJ, and COG AALL03N1 was approved by the National Cancer Institute and the institutional review boards of participating institutions. Informed consent was obtained from patients, parents, or guardians in accordance with the Declaration of Helsinki.
A preliminary TPMT clinical genotype was based on polymerase chain reaction tests for three known no-function variants: rs1800462, rs1800460, and rs1142345 (contributing to *2, *3A, and *3C alleles). 50 Considering the impact of anemia and blood transfusion on TPMT enzymatic activity, 50 ,51 blood samples were collected after remission induction and 90 days after erythrocyte transfusions.
COG patients received a protocol-planned dose of 75 mg/m 2 /day, which was adjusted based on the degree of leukopenia and toxicities. SJ patients received 50-75 mg/m 2 /day, with those heterozygous for TPMT clinical genotype receiving a starting mercaptopurine dose of 50-60 mg/ m 2 /d. Mercaptopurine dosage was also titrated based on TPMT activity and thiopurine metabolites. To assess tolerability, dose intensity for each patient was estimated as the total cumulative prescribed dose/cumulative protocol dose. 21, 25 Genotyping and GWAS Germline DNA from blood or bone marrow obtained at remission from SJ (n 5 306) and COG (n 5 578) patients was typed using Affymetrix Genome-Wide Human SNP Array 6.0 (or GeneChip Human Mapping 500K) and by Illumina Human Exome Beadchip Array. 21 For SNPs not interrogated on the arrays, imputation was performed using the 1000 Genomes Project (http://www.1000genomes.org) as the reference with MaCH-Admix software (University of North Carolina). Imputed SNPs with an MAF <1% were excluded. Genetic ancestries (European, African, Native American, and Asian) were determined in 306 SJ and 657 COG patients using STRUCTURE, 52 and either treated as continuous variables or used to categorize patients as white (European ancestry >90%), black (African ancestry >70%), Hispanics (non-black patients with Native American ancestry >10%), Asian (Asian ancestry >90%), and "other" groups. We also identified additional variants by sequencing the TPMT gene in SJ patients (n 5 296; see Supplementary Table S3 online), as described. 53 Genotype calls were coded as 0, 1, or 2 for the number of B alleles (AA, AB, or BB), assuming an additive genetic model. To identify covariates, we used multiple linear regression to evaluate the association between TPMT activity and variables, including age (years) and ancestry (as % European, African, Asian, and Native American ancestries) 52 as continuous variables. After excluding SNPs with a call rate <95%, over nine million SNPs (including 578,233 typed SNPs) were interrogated in the initial GWAS for TPMT activity in the SJ and COG cohorts separately. A meta-analysis was performed by combining the GWAS results from SJ and COG using Stouffer's Z-score method. 54 To determine non-TPMT genetic covariates for TPMT activity, we conducted a second GWAS that included the covariates of ancestry and age as continuous variables, and TPMT clinical genotype coded as 0 (wild-type), 1 (heterozygous), or 2 (homozygous) for the number of *2, *3A, or *3C alleles. A meta-analysis was performed as described above.
TPMT activity GWAS in HapMap LCLs
We obtained 177 Epstein-Barr virus-transformed LCLs, including 89 CEPH (forming 30 CEPH family trios) and 88 YRI (forming 30 YRI family trios) genotyped in the International HapMap project, from Coriell (Camden, NJ http://www.ccr.coriell.org). TPMT activity for each cell line was determined. 8, 9 Genotypes for approximately four million SNPs were obtained from release 28 of the International HapMap Project (http://www.hapmap.org). A GWAS for TPMT activity was performed using genetic ancestry as a continuous variable.
Permutation-based GWAS in patients
To compare GWAS results from patients to those from HapMap LCLs, it was necessary to adjust for the smaller sample size of the LCLs to achieve the same level of statistical power. For each permutation test, we randomly selected 177 patients from either SJ or COG cohorts (the same as the number of HapMap LCLs; n 5 177) in 20 independent permuted GWASs. Within each permutation, the genotype-phenotype association of 169,521 SNPs on the Illumina Exome Array was evaluated using the same method as in the HapMap GWAS.
Classification performance of TPMT genotype for phenotype Sensitivity, specificity, positive predictive value, and negative predictive value of TPMT genotypes for dichotomized TPMT phenotypes were calculated using the numbers of patients with true-positive, false-positive, true-negative, and false-negative results (see Supplementary Figures S5  and S6 online) . The classification performance of TPMT genotypes was evaluated in terms of receiver operating characteristic curves (see Supplementary Figures S5 and S6 online) .
Statistics
The Mann-Whitney U test was used to compare continuous variables between groups and the v 2 test was used to compare categorical variables. A multivariate general linear model was used to test covariates for their association with the dependent variables. The LD was calculated using Haploview version 4.2.
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